anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cisplatin-induced ototoxicity (CIO), characterized by irreversible and progressive bilateral hearing loss, is a prevalent adverse effect of cisplatin chemotherapy. Alongside clinical risk factors, genetic variants contribute to CIO and genome-wide association studies (GWAS) have highlighted the polygenicity of this adverse drug reaction. Polygenic scores (PGS), which integrate information from multiple genetic variants across the genome, offer a promising tool for the identification of individuals who are at higher risk for CIO. Integrating large-scale hearing loss GWAS data with single cell omics data holds potential to overcome limitations related to small sample sizes associated with CIO studies, enabling the creation of PGSs to predict CIO risk.
RESULTS: We utilized a large-scale hearing loss GWAS and murine inner ear single nuclei RNA-sequencing (snRNA-seq) data to develop two polygenic scores: a hearing loss PGS (PGSHL) and a biologically informed PGS for CIO (PGSCIO). The PGSCIO included only variants which mapped to genes that were differentially expressed within cochlear cells that showed differential abundance in the murine snRNA-seq data post-cisplatin treatment. Evaluation of the association of these PGSs with CIO in our target CIO cohort revealed that PGSCIO demonstrated superior performance (P = 5.54 × 10- 5) relative to PGSHL (P = 2.93 × 10- 3). PGSCIO was also associated with CIO in our test cohort (P = 0.04), while the PGSHL did not show a significant association with CIO (P = 0.52).
CONCLUSION: This study developed the first PGS for CIO using a large-scale hearing loss dataset and a biologically informed filter generated from cisplatin-treated murine inner ear snRNA-seq data. This innovative approach offers new avenues for developing PGSs for pharmacogenomic traits, which could contribute to the implementation of tailored therapeutic interventions. Further, our approach facilitated the identification of specific cochlear cells that may play critical roles in CIO. These novel insights will guide future research aimed at developing targeted therapeutic strategies to prevent CIO.
The invention discloses an attenuated bacteria vector tuberculosis vaccine carrying tuberculosis genes as well as a preparation method and application thereof. The preparation process includes the following steps: firstly, structuring a eukaryotic expression plasmid containing mycobacterium tuberculosis Ag85B and ESAT-6Agb5B genes; and secondly, using the electroporation method to convert the structure eukaryotic expression plasmid into attenuated Salmonella typhimurium which can stably express mycobacterium tuberculosis proteins. The combined utilization of Salmonella typhimurium SL7207 (pVAX-1-ESAT6-Ag85B) and BCG can achieve greater immune protective effect in resisting mycobacterium tuberculosis infection than by the BCG only; and the SIgA level of mucosa and serum produced by the Salmonella typhimurium SL7207 (pVAX-1-ESAT6-Ag85B) and BCG combined is higher than BCG and DNA vaccines. In addition, the Salmonella typhimurium SL7207 (pVAX-1-ESAT6-Ag85B) has greater immune protective ability than DNA vaccines or Salmonella typhimurium SL7207 (pVAX-1-Ag85B). The invention has the advantages of simple method, low cost, and convenient use, and can not only resist Salmonella typhosa infection, but also achieve immune protection against mycobacterium tuberculosis infection. Moreover, the stable expression of the mycobacterium tuberculosis proteins after being immunized can induce mucosal and systematic immune responses, and the invention has remarkable economic benefits.
ERBITUX can cause cardiopulmonary arrest. Cardiopulmonary arrest or sudden death occurred in 2% of 208 patients treated with radiation therapy and ERBITUX in BONNER. Three patients with prior history of coronary artery disease died at home, with myocardial infarction as the presumed cause of death. One of these patients had arrhythmia and one had congestive heart failure. Death occurred 27, 32, and 43 days after the last dose of ERBITUX. One patient with no prior history of coronary artery disease died one day after the last dose of ERBITUX. 

In EXTREME, fatal cardiac disorders and/or sudden death occurred in 3% of 219 patients treated with a cetuximab product in combination with platinum-based therapy and fluorouracil. 

Carefully consider use of ERBITUX with radiation therapy or platinum-based therapy with fluorouracil in patients with SCCHN with a history of coronary artery disease, congestive heart failure, or arrhythmias. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX [see Warnings and Precautions (5.6)].
Gait is altered in Parkinson's disease (PD) patients. It has been shown that treadmill training is useful in improving the gait's parameters in patients in early-moderate stages of disease. Moreover, it has been shown that the music, exploiting the entrainment, is effective in order to ameliorate several gait parameters, as step lenghts and cadence. No data are available about the effectiveness of the association between treadmill and music. The aim of this study is to evaluate the effect of a gait training using musical treadmill in patients in stages I-II-III Hoehn \& Yahr (H\&Y).

100 patients with PD in early-moderate stage of disease will be enrolled. All patients will undergo an intensive treatment: 2 session of 20-minutes treadmill training per day, 5 times a week, for 4 weeks. Treadmill speed will be previously set at 20% less the confidence speed and progressively increased of 20%. All patients will be evaluat at the enrolment and at the end of the treatment. The outcome misures are: 6 Minute Walking Test and Timed Up and Go Test.
BACKGROUND: Natural Language Processing (NLP) and Large Language Models (LLMs) hold largely untapped potential in infectious disease management. This review explores their current use and uncovers areas needing more attention.
METHODS: This analysis followed systematic review procedures, registered with the Prospective Register of Systematic Reviews. We conducted a search across major databases including PubMed, Embase, Web of Science, and Scopus, up to December 2023, using keywords related to NLP, LLM, and infectious diseases. We also employed the Quality Assessment of Diagnostic Accuracy Studies-2 tool for evaluating the quality and robustness of the included studies.
RESULTS: Our review identified 15 studies with diverse applications of NLP in infectious disease management. Notable examples include GPT-4's application in detecting urinary tract infections and BERTweet's use in Lyme Disease surveillance through social media analysis. These models demonstrated effective disease monitoring and public health tracking capabilities. However, the effectiveness varied across studies. For instance, while some NLP tools showed high accuracy in pneumonia detection and high sensitivity in identifying invasive mold diseases from medical reports, others fell short in areas like bloodstream infection management.
CONCLUSIONS: This review highlights the yet-to-be-fully-realized promise of NLP and LLMs in infectious disease management. It calls for more exploration to fully harness AI's capabilities, particularly in the areas of diagnosis, surveillance, predicting disease courses, and tracking epidemiological trends.
In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. In the control group, cryosurgery will be performed using liquid nitrogen spray in each AK lesion; this will be done at visit 1 and, if necessary, also at visits 2-5. At visits 2-6, the efficacy of the treatment will be evaluated by the observer by documenting all existing and newly appearing AKs in the face.
The proposed intervention consists of 6 remotely-delivered sessions; Weeks 1, 2, 4, 6, 7, and 8, with weeks 3 and 5 being "rest weeks". Session 1 will be 60-90 mins, Session 2 will be \~60 mins, and remaining visits are \~45 mins. The investigators propose a methodological innovation for CBT-I, which involves conducting 15-minute sessions every other month during the BWL intervention. Prior to these maintenance sessions, participants in the CBT-I+BWL group will complete electronic sleep diaries for one week and interventionists will use this information in sessions to sustain and enhance long-term outcomes by using MI to reinforce application of CBT-I session content.
The invention discloses a recombinant human growth hormone fusion protein and application thereof. The recombinant human growth hormone fusion protein consists of human growth hormone, connecting peptide and human IgG4 antibody Fc fragment mutant. The invention also discloses a vector, a host cell and a screening method for efficiently expressing the recombinant human growth hormone fusion protein in mammalian cells. The invention also discloses a method for measuring the binding force between the recombinant human growth hormone fusion protein and a human growth hormone receptor. Compared with non-fusion human growth hormone, the affinity between the recombinant human growth hormone fusion protein and a human growth hormone receptor is improved by 5 times, and the biological activity (cell proliferation activity) is improved by more than 3 times. In medical application, the recombinant human growth hormone fusion protein can be used as an upgrade product of non-fusion human growth hormone.
Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
Centrosomes are the major microtubule organizing centers of animal cells. Supernumerary centrosomes are a common feature of human tumors and associated with karyotype abnormalities and aggressive disease, but whether they are cause or consequence of cancer remains controversial. Here, we analyzed the consequences of centrosome amplification by generating transgenic mice in which centrosome numbers can be increased by overexpression of the structural centrosome protein STIL. We show that STIL overexpression induces centrosome amplification and aneuploidy, leading to senescence, apoptosis, and impaired proliferation in mouse embryonic fibroblasts, and microcephaly with increased perinatal lethality and shortened lifespan in mice. Importantly, both overall tumor formation in mice with constitutive, global STIL overexpression and chemical skin carcinogenesis in animals with inducible, skin-specific STIL overexpression were reduced, an effect that was not rescued by concomitant interference with p53 function. These results suggest that supernumerary centrosomes impair proliferation in vitro as well as in vivo, resulting in reduced lifespan and delayed spontaneous as well as carcinogen-induced tumor formation.
A medicinal agent comprising acetylcysteine in isotonic 0.9% NaCl soln. as carrier liq. is claimed. USE/ADVANTAGE - The agent is able to diffuse into animal and human cells where the acetylcysteine promotes restoration of the protein-enzyme deficiency existing in allergics (e.g. adenosine- deaminase enzyme deficiency) and stimulates prodn. of steroid hormones and neuro transmitters such as acetylcholine and dopamine and ADP and ATP in the citrate cycle (breathing chain) which are important for muscle tensioning and relaxation such as in cramping of the bronchia and bronchioles in bronchitis and bronchial asthma, so that the agent is esp. useful in treating these conditions. The agent is taken orally at long time intervals to avoid feedbac
The highest documented dosage of sofosbuvir was a single dose of sofosbuvir 1200 mg (three times the recommended dosage) administered to 59 healthy subjects. In that trial, there were no untoward effects observed at this dosage level, and adverse events were similar in frequency and severity to those reported in the placebo and sofosbuvir 400 mg treatment groups. The effects of higher dosages are not known.

No specific antidote is available for overdose with SOVALDI. If overdose occurs, the patient must be monitored for evidence of toxicity. Treatment of overdose with SOVALDI consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. A 4-hour hemodialysis session removed 18% of the administered dose.
The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
The Liangfu formula, as described in 'Liangfang Jiye', is well-known for its efficacy in treating stomach pain, abdominal pain, and dysmenorrhea. This research aimed to investigate the pharmacokinetics and tissue distribution of 5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-phenyl-3-heptanone (DPHA), Galangin, Kaempferide, 5-Hydroxy-1,7-diphenyl-3-heptanone (DPHC), α-Cyperone, and Nootkatone in vivo using an LC-MS/MS method. The method successfully separated the six active components and internal standards (Chrysin and Yakuchinone-A) on an XB-C18 column with a mobile phase of 0.2 ‰ formic acid water-acetonitrile. It demonstrated good linearity with a correlation coefficient (r2) ≥ 0.9911 and a lower limit of quantification (LLOQ) of 5-80 ng/mL for the different components. Precision, accuracy, matrix effects, and recovery rates were within acceptable ranges. Pharmacokinetic analysis revealed significant differences in parameters between primary dysmenorrhea (PD) and normal rats (especially AUC, Tmax, and CLz/F). Tissue distribution showed that the six active components of the herbal pair Alpinia officinarum Hance-Cyperus rotundus L. (HPAC) extract was primarily distributed in the liver, lung, and kidney. This study offers valuable insights into the potential mechanisms of action and drug development for treating PD.
Preparations for sexual enhancement may comprise a lubricant material along with one or more gel battery device. The gel battery devices may be fabricated from a gel anode material and a gel cathode material. The gel batteries may further comprise a gel electrolyte material. The gel materials may be in the form of thin films or capsules. The gel batteries, their anode, cathode, and electrolyte materials may all be non-toxic for an application to an animal. One or more devices for sexual enhancement may be contacted with the sexual enhancement preparation. The preparations or the devices with the preparations may be applied to one or more tissues of an animal.
1,155,036. Injectionable substances. E. A. BROWN. 8 July, 1966, No. 30836/66. Heading A5B. Therapeutic compositions for injection comprise finely divided solid microparticles of a metabolizable substance having an active drug physically incorporated into the structure of said micro-particles, said micro-particles being suspended in a physiologically accepted or non-toxic liquid carrier. The carrier is preferably aqueous or an oil, and when the latter is used the suspension may subsequently be suspended or emulsified in an aqueous medium; alternatively, the carrier may be a secondarily active substance, e.g. solutions of antihistamines, corticosteroid hormones and/or antiserum. The microparticles may be those of a protein, proteose, protamine or amino acid, preferably glycine or tyrosine. The microparticles incorporating the active drug may be encapsulated with for example celluloses (e.g. cellulose acetate or butyrate, methylcellulose, hydroxyethylcellulose or ethylcellulose); low molecular weight polymers of polyethylene, polypropylene, methylmethacrylates or methacrylates; gelatin; silicone derivatives; or salts (e.g. NaCl, KCl or CaCl 2 ), employing conventional methods. The active drug may be incorporated in the micro-particles by dissolving the metabolizable substance in a liquid (eg water) containing an active drug dissolved therein; depositing the metabolisable substance having the active drug incorporated therein from the liquid (e.g. by lyophilization or by precipitation from a saturated solution of the metabolizable substance in the liquid); drying the metabolizable substance and breaking up the particles to micro-size, and finally suspending the metabolizable substance in the carrier. The invention is particularly applicable for administering drugs which are normally likely to produce adverse side-effects such as allergens, antigens, venoms, vaccines, toxins, serums and extracts of pollens, moulds and animal danders; and also vitamins such as C and B 12 , antitussives, antihistamines, analgesics, narcotics, hypnotics, sedatives, tranquillizers, hormones and insulin.
Cannabidiol (CBD) is the most relevant nonpsychostimulant phytocompound found in Cannabis sativa. CBD has been extensively studied and has been proposed as a therapeutic candidate for neuroinflammation-related conditions. However, being a highly lipophilic drug, it has several drawbacks for pharmaceutical use, including low solubility and high permeability. Synthetic polymers can be used as drug delivery systems to improve CBD's stability, half-life, and biodistribution. Here, we propose using a synthetic polymer as a nanoparticulate vehicle for CBD (NPCBD) to overcome the pharmacological drawbacks of free drugs. We tested the NPCBD-engineered system in the context of ischemic events in a relevant oxygen and glucose deprivation (OGD) model in primary cortical cells (PCC). Moreover, we have characterized the inflammatory response of relevant cell types, such as THP-1 (human monocytes), HMC3 (human microglia), and PCC, to NPCBD and observed a shift in the inflammatory state of the treated cells after the ischemic event. In addition, NPCBD exhibited a promising ability to restore mitochondrial function after OGD insult in both HMC3 and PCC cells at low doses of 1 and 0.2 μM CBD. Taken together, these results suggest the potential for preclinical use.
BACKGROUND: The purpose of this study is to determine whether preoperative facet fluid on MRI can help predict segmental instability (SI) after decompression surgery.
METHODS: We analyzed 34 patients (14 men and 20 women, a total of 37 segments) who underwent decompression for degenerative lumbar spinal stenosis from June 2011 to August 2019 at a single institution. Mean age at the time of operation was 67.8. Postoperative assessment was performed uniformly 12 months (11~15 months) after the surgery. Preoperative facet fluid on MRI, pre- and postoperative slip percentage, and segmental motion on lumbar lateral neutral and flexion-extension (LFE) radiographic images were measured. Visual Analog Scale (VAS) and necessities of interventional procedure or medication was also assessed for clinical outcomes.
RESULTS: No significant association was found between preoperative facet fluid indices and pre- or postoperative slip percentage (P=0.134) and segmental motion (P=0.936). There were no significant association also between facet fluid indices and VAS of back or leg (P=0.997 and P=0.437 respectively).
CONCLUSIONS: Preoperative facet fluid is not a predictive index of postoperative segmental instability or clinical outcome. Without segmental instability on LFE radiographic images, the presence of facet fluid in MRI is not an absolute indication for fusion.
A hair treatment accessory for use with a hair styling apparatus includes a substrate base for mounting to a hair styling apparatus and a treatment agent disposed on the substrate base. The treatment agent is applied to one of the hair or skin of a subject during use of the hair styling apparatus. The treatment agent may include a conditioning, strengthening, repairing or revitalizing fluid. The treatment agent may include a conditioning oil. The conditioning oil may include ARGAN oil with or without silicon. The substrate base may include an irregular surface dimensioned to assist in retention of the treatment agent on the substrate base. The irregular surface may include open cells or channels. The irregular surface may be formed through a sintering process.
The miR-497-195 cluster facilitates the occurrence and development of cancer. This study aims to investigate whether the miR-195-497 cluster could regulate the progression of colorectal cancer by regulating the common target gene, FOS-related antigen 1 (FRA1). Overexpression of the miR-195/497 vector was used to evaluate the effect of overexpression of miR-195-497 clusters on the biological behavior of colon cancer cells. In animal experiments, tumor growth and metastasis were recorded by constructing a nude mouse model of a subcutaneously implanted tumor. miR-195 and miR-497 were expressed to varying degrees in Caco-2, LoVo, and HT-29 cells. Overexpression of miR-195/497 and inhibition of FRA1 decreased HT-29 cell proliferation, inhibited cell invasion and migration, and promoted Epithelial-mesenchymal transition (EMT). In vivo experiments showed that the overexpression of miR-195/497 or inhibition of FRA1 inhibited tumor growth, affected EMT in tumor cells, and inhibited the expression of FRA1. Additionally, the aforementioned conditions had the best effect when used together. The miR-195-497 cluster can regulate the proliferation, EMT, invasion, and migration of colorectal cancer cells by regulating the common target gene FRA1, thereby affecting the development of colorectal cancer.
The invention relates to a solid preparation with cefotiam hexetil as an active component. The solid preparation is used for treating infections caused by sensitive organisms. The invention aims at solving defects of existing technologies. The invention provides a novel preparation for the majority of patients and medical professionals. The novel preparation has advantages of rapid disintegration, fast absorbance, and convenient administration. With the preparation, bioavailability and blood drug level of medicine can be improved, peak-reaching time can be shortened, and bactericidal effects can be improved. According to the invention, cefotiam hexetil is adopted as a raw material, certain auxiliaries with a certain ratio are added to the raw material, and the oral solid preparation is prepared with a common technology in pharmaceutics.